Browse All Grants
20,252 grants found
Showing 1,961 – 1,980 of 20,252 grants
SOX2 acts in the 3D genome of squamous cancer
PROJECT SUMMARY As one of the most common and deadly cancer types worldwide, squamous cancer can occur to diverse organ sites including lung, esophagus, upper digestive tracts, cer...
Cancer-specific dependencies within the NuRD chromatin remodeler complex: new targets and chemical tools
PROJECT SUMMARY/ABSTRACT Histone deacetylases (HAT) are zinc-dependent enzymes that catalyze the removal of acetyl groups from the epsilon amine of lysine side chains. These protei...
New tools for quantitative non-invasive recording of biochemical signals
ABSTRACT Chimeric antigen receptor (CAR) T-cells are a revolutionary cancer treatment, with the particular benefit of generating memory T-cells that can last for years and suppress...
Translating Hyperpolarized 13C MRI as a Novel Tool to Predict Treatment Response in Pancreatic Cancer
Project Summary/Abstract This project is designed to develop a new approach to monitor and predict treatment response in patients with pancreatic ductal adenocarcinoma (PDA) using...
Inhibiting Rev1-mediated translesion DNA synthesis for cancer therapy
Project Summary/Abstract Prostate cancer is a leading cause of cancer death in American men. The National Cancer Institute estimated that there would be ~268,490 new cases of prost...
Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling
PROJECT SUMMARY/ABSTRACT Esophageal squamous cell carcinoma (ESCC) accounts for over 80% of esophageal cancer cases and has a poor prognosis, largely due to the absence of symptoms...
Targeting actionable liabilities in Merlin-deficient breast cancer
ABSTRACT During tumor progression, loss of cell:cell adhesion and detachment from the extracellular matrix induces dynamic reorganization of the cytoskeleton, formation of invadopo...
Control of the MYC Super-Enhancer Complex in FLT3-ITD Acute Myeloid Leukemia
PROJECT SUMMARY/ABSTRACT Acute myeloid leukemia (AML) is an aggressive blood cancer with a 5-year expected survival rate of less than 30%. Internal tandem duplications (ITD) of Fms...
The non-canonical Collagen I-DDR1 signaling regulating protein synthesis during metastasis
PROJECT SUMMARY The activation of signaling tumor cells via the tumor micrenvironment (TME) to undergo metastasis in bladder cancer is understudied. Clinically, increased Col I dep...
Mechanisms determining tumor-selective potency of RAS pathway inhibitors
Summary The RAS/RAF/MEK/ERK (RAS/MAPK) signaling pathway is an established driver of many cancers, commonly hyperactivated by genetic alterations in RAS or BRAF. RAF and MEK inhibi...
Exploring the interaction of lipid metabolism with the hexosamine pathway and tumor growth
PROJECT SUMMARY Cancer metabolic reprogramming is key for the adaptation of the tumors to their harsh microenvironments. Elevated LD abundance in tumors is frequently detected and...
Harnessing Cytomegalovirus (CMV)-specific T-cells for pancreatic cancer immunotherapy
Abstract Immunotherapy is a promising therapeutic strategy for many cancers. Anti-tumor immune responses are elicited against neoantigens that arise from genetic alterations within...
Heterogeneous Genetic Architecture in Lung Cancer Risk
Title: Heterogeneous genetic architecture in lung cancer risk Project Summary/Abstract Lung cancer is a multifactorial disease driven by environmental exposures, inherited germline...
Maximizing tumor responses to targeted radiotherapy with a conditionally activated membrane binding probe
Project Abstract: The recent FDA approvals (Lutathera, Azedra, Pluvicto) and the swell of promising experimental agents in clinical trials underscore the surging enthusiasm to inve...
Interrogating roles for REST in small cell lung cancer therapy response and resistance
SUMMARY Small cell lung cancer (SCLC) is a lethal tumor type characterized by exquisite response to chemotherapy followed by rapid emergence of chemoresistance. Addition of PDL-1 i...
Targeted degradation of KRAS oncoproteins triggers antitumor immunity and abolishes lung tumor
Summary: Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer death worldwide. KRAS is the most frequently mutated oncogene in lung adenocarcinoma, the most co...
The Role of the Tumor Microenvironment in Resistance to Oncogenic KRAS Inhibition in Lung Cancer
PROJECT SUMMARY Inhibitors against mutant KRAS—the oncogene once deemed undruggable—are impressively showing tumor control in preclinical testing, entering the clinic for testing i...
Targeting MDM4 in Rare Refractory Ovarian Cancer Sub-Types
Activation of wild-type (wt) p53 tumor suppressor is sufficient to kill tumor cells, even if other gene defects are present. Cisplatin is a p53-dependent drug that is heavily used...
Preclinical studies of non-nucleoside DNMT3A/3B inhibitors
PROJECT SUMMARY/ABSTRACT DNA cytosine methylation yielding 5-methylcytosine (5mC) is a major epigenetic modification involved in the regulation of chromatin structure and gene expr...
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor
PROJECT SUMMARY Lung cancer is the leading cause of cancer-related death in men and women in Western countries, with non- small cell lung cancer (NSCLC) accounting for ~85% of all...